Spread over 79,000ft², the facility is equipped with packaging lines and clean rooms to package and ship prescription and over-the-counter products across the US market
The plant will expand the packaging capacity of essential drugs and strengthen the firm’s biopharma supply chain. (Credit: Christine Sandu on Unsplash)
Pharmaceutical company Granules India has announced the opening of its new packaging facility through its Granules Consumer Health (GCH) step-down subsidiary in Manassas, Virginia, US.
Spread over 79,000ft², the facility is equipped with packaging lines and clean rooms to package and ship prescription and over-the-counter products across the US market. The firm has leased the space at the Parkway 66 property at 7413 Cushing Road in Manassas.
Announced in 2022, the plant will expand the packaging capacity of essential drugs and strengthen the firm’s biopharma supply chain.
Recently, the packaging facility secured the US Food and Drug Administration (FDA) approval with zero 483 observations.
Granules India chairman and managing director Krishna Prasad Chigurupati said: “Granules Consumer Health’s packaging facility will improve resilience in our supply chain as well as improve our reaction time.
“The facility will enable us to meet fast-moving consumer shifts as well as reduce lead times for critical prescriptions products that are in shortage.”
The addition of the new plant, set up at an investment of around $12.5m, will help Granules to be vertically integrated from Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs) and Finished Dosages (FDs) to packaging.
Chigurupati said: “We have nearly 200 employees in Virginia with a large majority of them first-generation Indians.”
Established in 1991, Granules India distributes products to customers in regulated and semi-regulated markets and has a global presence in more than 80+ countries with offices across India, the US and the UK.
It has seven manufacturing facilities out of which six are in India and one in the US.
The business makes finished dosages, pharmaceutical formulation intermediates, and active pharmaceutical components along with products like acetaminophen, ibuprofen, and guaifenesin.